Question special
Lead Moderator

Welcome to the NEJM Forum on the original research article just published in NEJM titled “A randomized, controlled trial of 3.0mg Liraglutide in weight management.” I'd like to thank the panel of experts in advance for their time and participation in this forum. I will be posting one question every day along with my co-moderators. I'm looking forward to the next 10 days and hope that we will have an interesting and engaging discussion. To start of the discussion, I would like to ask if the panel of experts would share their thoughts about the different proposed mechanisms for which Liraglutide mediates weight loss. In lower doses for diabetes management, GLP-1 agonists class drugs have been shown to increase glucose-dependent insulin secretion, decrease glucagon secretion, delay gastric emptying and increase satiety. Would there be any additional mechanistic benefits using a higher dose of treatment with 3.0mg, or is it a dose effect with the higher dosage producing a larger effect?